Page last updated: 2024-09-03

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Cardiomyopathies

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid has been researched along with Cardiomyopathies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Al Azzam, W; Antoni, G; Bergström, M; Biswas, S; Chen, C; Cheriyan, J; Cleveland, M; Cookson, L; Falk, RH; Galette, P; Janiczek, RL; Kwong, RY; Lukas, MA; Millns, H; Richards, D; Schneider, I; Solomon, SD; Sörensen, J; Storey, J; Thompson, D; van Dongen, G; Vugts, DJ; Wall, A; Wechalekar, A; Wikström, G1

Trials

1 trial(s) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Cardiomyopathies

ArticleYear
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
    BMC cardiovascular disorders, 2022, 02-13, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Amyloidosis; Antibodies, Monoclonal; Carboxylic Acids; Cardiomyopathies; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Myocardium; Positron-Emission Tomography; Predictive Value of Tests; Pyrrolidines; Serum Amyloid P-Component; Time Factors; Treatment Outcome; United Kingdom; United States; Ventricular Function, Left; Ventricular Remodeling

2022